Clinical Trial Update: SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial evaluates a third-line treatment for recurrent/metastatic colorectal cancer using SBRT followed by a PD-1 inhibitor, bevacizumab, an…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• PD-1 inhibitor
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: Shanghai Zhongshan Hospital | Conditions: Colorectal Neoplasms | Phase 2 | Status: NOT_YET_RECRUITING